Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Crisantaspase→

Crisantaspase Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
9002-93-1
Molecular formula
C612H988N168O184S4
Molecular weight
~138000 g/mol
Drug class
Recombinant Erwinia chrysanthemi L-asparaginaseantineoplastic enzyme
Mechanism of action
Catalyses hydrolysis of circulating L-asparagine to L-aspartic acid and ammonia. Depletion of extracellular asparagine limits protein synthesis and survival of leukaemic lymphoblasts that have low asparagine-synthetase capacity.
Indications / reported uses
  • As a component of multi-agent chemotherapy for acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma in adults and children aged 1 month and older who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase

Sources: EMA EPAR — Enrylaze · EMA product information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Crisantaspase Environmental Risk Assessment (ERA) (the Crisantaspase ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.